Supriya Lifescience Limited (SUPRIYA.NS)
INR 638.35
(-1.05%)
INR 638.35
(-1.05%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.21 Billion INR | 12.31% |
| 2022 | 8.2 Billion INR | 11.64% |
| 2021 | 7.34 Billion INR | 64.81% |
| 2020 | 4.45 Billion INR | 32.52% |
| 2019 | 3.36 Billion INR | 32.95% |
| 2018 | 2.53 Billion INR | 3.12% |
| 2017 | 2.45 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.12 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 9.21 Billion INR | 12.31% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 9.21 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 8.43 Billion INR | 0.0% |
| 2022 Q4 | 8.2 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 7.61 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 8.2 Billion INR | 11.64% |
| 2021 Q2 | 5.04 Billion INR | 0.0% |
| 2021 FY | 7.34 Billion INR | 64.81% |
| 2021 Q4 | 7.34 Billion INR | 0.0% |
| 2020 Q3 | 3.56 Billion INR | 0.0% |
| 2020 FY | 4.45 Billion INR | 32.52% |
| 2020 Q4 | 4.45 Billion INR | 24.94% |
| 2019 FY | 3.36 Billion INR | 32.95% |
| 2018 FY | 2.53 Billion INR | 3.12% |
| 2017 FY | 2.45 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Biocon Limited | 560.7 Billion INR | 98.357% |
| Blue Jet Healthcare Limited | 10.58 Billion INR | 12.996% |
| Concord Biotech Limited | 17 Billion INR | 45.832% |
| Dishman Carbogen Amcis Limited | 95.81 Billion INR | 90.385% |
| Jubilant Ingrevia Limited | 47.31 Billion INR | 80.531% |
| Lyka Labs Limited | 1.56 Billion INR | -487.808% |
| Panacea Biotec Limited | 12.4 Billion INR | 25.747% |
| Piramal Pharma Limited | 153.11 Billion INR | 93.983% |
| SMS Lifesciences India Limited | 3.9 Billion INR | -135.901% |
| Syngene International Limited | 61.51 Billion INR | 85.024% |
| TAKE Solutions Limited | 881.05 Million INR | -945.614% |
| Zota Health Care Limited | 2.28 Billion INR | -303.47% |